The Food and Drug Administration (FDA) has posted a discontinuation notice for Vitekta (elvitegravir; Gilead) 85mg and 150mg tablets. The affected product is supplied in 30-count bottles with NDC #61958-1301-1 and #61958-1302-1. 

Vitekta, an HIV-1 integrase strand transfer inhibitor, was approved in October 2014 for use in combination with an HIV protease inhibitor co-administered with ritonavir and other antiretroviral agents for the treatment of HIV-1 infection in treatment-experienced adults. 

Related Articles

Gilead has stated that the decision to permanently discontinue manufacturing is a business decision and is not due to product safety or efficacy. 

For more information call (800) 445-3235 or visit